Dyne Therapeutics, who received early funding from CureDuchenne, has received FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy.
Hawken Miller is a journalist, bringing his experience writing for outlets like The Washington Post and BioNews, along with his personal experience living with Duchenne muscular dystrophy, to CureDuchenne. Learn more about Hawken here.
Myosana Therapeutics, a biotech company based in Seattle, WA, closed a new $5 million financing round to support further development of their non-viral gene therapy technology for the treatment of [...]
See full PRESS RELEASE: https://www.globenewswire.com/news-release/2022/10/13/2534198/0/en/PepGen-Presents-Data-from-its-Duchenne-Muscular-Dystrophy-Program-at-World-Muscle-Society-Congress.html
Dyne Therapeutics, who received early funding from CureDuchenne, presented promising preclinical data from their Duchenne Exon 51 and 53 programs at the World Muscle Society Congress. This was Dyne’s first […]
Edgewise Therapeutics, which received early funding from CureDuchenne, announced positive 6-month interim results from the ongoing ARCH study, an open label study of EDG-5506 in adults with Becker muscular dystrophy. Edgewise […]
CureDuchenne, as an early investor in Avidity Biosciences, is excited to share the announcement of the Phase 1/2 EXPLORE44™ clinical trial of AOC 1044 in healthy volunteers and participants with […]
At the core of the MAA submission are positive data from the pivotal Phase 2b VISION-DMD study which comprised a (1) 24-week period to demonstrate efficacy and safety of vamorolone […]
[Download the Report]